FourKites’ Industry-First Order Intelligence Hub Extends Real-Time Visibility to the Entire Order Lifecycle
FourKites® , the world’s leading real-time supply chain visibility platform, today introduced its Order Intelligence Hub, a new single-pane-of-glass view of the entire lifecycle of every order. By integrating order data, load information across modes, yard shipments, inventory visibility and other critical third-party systems, such as warehouse management systems and order management systems, shippers and their supply chain partners now have a powerful new tool to eliminate inefficiencies, manage exceptions, reduce expenses and increase customer satisfaction at every step of an order’s journey. With the goal of breaking down silos across systems, this solution was developed in close collaboration with major consumer packaged goods (CPG) customers and driven by insights from some of the largest companies in the Consumer Brand Association, which champions more than 1,700 leading CPG brands.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210929005410/en/
FourKites’ Industry-first Order Intelligence Hub Extends Real-Time Visibility to the Entire Order Lifecycle (Graphic: Business Wire)
As part of the recently announced Supply Chain Health and Performance Task Force, the mission of which is to increase visibility and ease supply chain pressures across the CPG industry, FourKites worked closely with Consumer Brands and 15 of its members to identify common pain points and create a solution that would address those challenges by breaking down silos between teams and systems, and leveraging the scale of the FourKites network to provide unprecedented visibility into the CPG supply chain ecosystem. Through shared dashboards, participating members can take advantage of a real-time view of facilities, lanes and interchanges causing the most inefficiencies for CPG companies. With Order Intelligence Hub, users can drill down into the line-item level impacts of bottlenecks, and can then collaborate across teams to resolve those inefficiencies.
“Collaboration is essential for building modern, resilient supply chains,” said Tom Madrecki, vice president of supply chain and logistics at Consumer Brands. “The Supply Chain Health and Performance Task Force — in partnership with FourKites — is bringing more visibility, agility and data sharing to our supply chain, allowing the CPG industry to better navigate future challenges and ensure the reliable delivery of essential goods.”
By eliminating silos and integrating disparate systems, FourKites’ Order Intelligence Hub enables collaboration and insight throughout the lifecycle of every order. Teams can much more effectively manage exceptions by identifying issues and their root causes in real time, anywhere. Customisable, persona-based dashboards provide every stakeholder group — from supply planning through to customer service and facilities management — with the data and metrics that matter most to them. And the entire community benefits from FourKites‘ market-leading network data set, collected via working with more of the world’s leading brands than any other visibility provider, including 18 of the top-20 F&B brands and nine of the top-10 CPG companies.
“The Order Intelligence Hub is a big milestone as we execute on our vision to connect the physical and digital worlds of warehouses, stores and transportation with real-time data and machine learning,” said Mathew Elenjickal, founder and CEO of FourKites. “Collaborating with our customers and other industry leaders, like Consumer Brands, in product development has enabled us to bring to market some of the most innovative solutions that address the industry’s most critical pain points.”
With the Order Intelligence Hub, FourKites builds on its long history of industry-first innovations, including multimodal purchase order tracking, which provides line-item level shipment detail using PO numbers, and Dynamic Yard, which gives enterprises the ability to proactively manage all of their facilities based on real-time, in-yard freight data and analytics. FourKites and its largest customers, which ship some of the world’s leading brands to locations around the world, have integrated previously siloed systems across customer service, transportation planning, supply/demand planning and warehouse management to enable internal stakeholder communication and insights throughout the lifecycle of every order.
About FourKites
FourKites® is a leading global supply chain visibility platform, extending visibility beyond transportation into yards, warehouses, stores and beyond. Tracking more than 2 million shipments daily across road, rail, ocean, air, parcel and courier, and reaching 176 countries, FourKites combines real-time data and powerful machine learning to help companies digitise their end-to-end supply chains. More than 620 of the world’s most recognised brands — including 9 of the top-10 CPG and 18 of the top-20 food and beverage companies — trust FourKites to transform their business and create more agile, efficient and sustainable supply chains. To learn more, visit https://www.fourkites.com/.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210929005410/en/
Contact information
Scott Johnston
European PR Director FourKites
+31 62 147 84424
scott.johnston@fourkites.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release
Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
